Zanubrutinib ‘Superior’ To Ibrutinib For Relapsed, Refractory CLL and SLL
From 64th ASH Annual Meeting & Exposition:
The phase III ALPINE trial demonstrates a progression-free survival advantage for zanubrutinib versus ibrutinib among patients with relapsed or refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma